Regeneron Pharmaceuticals

Yahoo Finance • 5 hours ago

4 stocks to watch on Friday: META, COST, REGN, XOM

[Five stacks of coloured coins with a graph line above] Richard Drury Stock index futures rose on Friday, as the Federal Reserve's preferred inflation gauge came inline. Here are four stocks to watch on the day: Meta Platforms (META [htt... Full story

Yahoo Finance • 6 hours ago

Regeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drug

[FDA Approved Products or Drugs] Olivier Le Moal Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) announced on Friday that the U.S. FDA approved a label expansion for its anti-cholesterol agent Evkeeza, marke... Full story

Yahoo Finance • 7 hours ago

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Ini... Full story

Yahoo Finance • 4 days ago

Humana initiated, Paycom upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: TD Cowen upgraded Paycom (PAYC) to Buy... Full story

Yahoo Finance • 5 days ago

Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 2... Full story

Yahoo Finance • 5 days ago

Communiqué de presse : Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP

Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP Recommandation pour les adultes et les adolescents, sur la base d’études de p... Full story

Yahoo Finance • 5 days ago

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated... Full story

Yahoo Finance • 5 days ago

Notable healthcare headlines for the week: Novo Nordisk, Hims & Hers and UnitedHealth in focus

Wall Street finished the week on a strong note as all three major market averages tagged record levels on Friday. For the week, the Nasdaq (COMP:IND), S&P 500 (SP500), and Dow (DJI) rose by 2.21%, 1.22%, and 1.05%, respectively. The S&P... Full story

Yahoo Finance • 6 days ago

REGN Quantitative Stock Analysis - Benjamin Graham

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep valu... Full story

Yahoo Finance • 7 days ago

Trump considering website for consumers to buy discounted prescription drugs - report

[Senior man researching about medicine online] blackCAT/E+ via Getty Images * The Trump administration is said to be discussing the launch of a website that would allow consumers to purchase prescription drugs less expensively by buying... Full story

Yahoo Finance • 7 days ago

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?

Regeneron unveiled what it calls "paradigm-shifting" test results for a drug that could prevent patients from developing multiple myeloma. Continue Reading View Comments... Full story

Yahoo Finance • 7 days ago

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

Inmazeb®(atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaireebolavirus Supply is being rushed to Democratic Republ... Full story

Yahoo Finance • 9 days ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 9 days ago

Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating “its first-in-class investigational alle... Full story

Yahoo Finance • 10 days ago

Drug developer Dualitas launches $65 million funding round

By Siddhi Mahatole (Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-relat... Full story

Yahoo Finance • 11 days ago

Benjamin Graham Detailed Fundamental Analysis - REGN

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep valu... Full story

Yahoo Finance • 11 days ago

BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a... Full story

Yahoo Finance • 14 days ago

Trump is said to force Big Pharma to lower drug prices within weeks

[New York Marks 24th Anniversary Of September 11 Terror Attacks] Michael M. Santiago/Getty Images News President Donald Trump is exerting pressure on major pharmaceutical companies to lower drug prices in the U.S. and wants them to commit... Full story

Yahoo Finance • 17 days ago

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on behalf of long-term... Full story

Yahoo Finance • 17 days ago

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent eff... Full story